NL-OMON42455已完成2 期
Decitabine-cytarabine chemotherapy in elderly AML and high risk MDS patients (> 65 years) with high early mortality risk - LUMC2015-02: Decitabine-cytarabine
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 19
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- patients with AML or high risk MDS (IPSS-R >= 4.5)
- •- > 65 years
- •- WHO performance score 0-2
- •- HCT-CI score >=2
- •- Written informed consent
排除标准
- •- Previous treatment with decitabine, azacitidine or intensive chemotherapy for this MDS/AML (treatment with chemotherapy for previous other diseases is acceptable)
- •- Acute promyelocytic leukemia
研究者
相似试验
进行中（未招募）
不适用
Decitabine-cytarabine chemotherapy in elderly AML and high risk MDS patients (> 65 years) with high early mortality riskAcute myeloid leukemia and high risk myelodysplasiaEUCTR2015-004896-60-NLeiden University Medical Center
尚未招募
不适用
Decitabine-cytarabine chemotherapy in elderly AML and high risk MDS patients (> 65 years) with high early mortality riskAcute myeloid leukemia (AML), Myelodysplasia (MDS), Acute myeloide leukemie, Myelodysplasie, Chemotherapy, ChemotherapieNL-OMON23606eiden University Medical Center (LUMC)20
已完成
不适用
Treatment With Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) With Acute Myeloid Leukemia: A Single Institution Experience.Acute Myeloid LeukemiaNCT03350152Hospices Civils de Lyon302
进行中（未招募）
3 期
"InDACtion" vs "3+7" Induction in AMLAcute Myeloid Leukemia (AML)NCT02172872European Organisation for Research and Treatment of Cancer - EORTC606
Unknown
1 期
Phase I/II Trial: BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia (AML)Acute Myeloid LeukemiaNCT01488344University Hospital Muenster140